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Renal cell carcinoma (RCC) is polyresistant to chemo- and
radiotherapy and biologicals, including TNF-related apoptosis-
inducing ligand (TRAIL). Sorafenib, a multikinase inhibitor
approved for the treatment of RCC, has been shown to sensitize
cancer cells toTRAIL-induced apoptosis, in particular by down-
regulation of the Bak-inhibitory Bcl-2 family protein Mcl-1.
Here we demonstrate that sorafenib overcomes TRAIL resis-
tance in RCCby amechanism that does not rely onMcl-1 down-
regulation. Instead, sorafenib induces rapid dissipation of the
mitochondrial membrane potential (m) that is accompanied
by the accumulation of reactive oxygen species (ROS). Loss of
m and ROS production induced by sorafenib are indepen-
dent of caspase activities and do not depend on the presence of
the proapoptotic Bcl-2 family proteins Bax or Bak, indicating
that both events are functionally upstream of themitochondrial
apoptosis signaling cascade. More intriguingly, we find that it
is sorafenib-induced ROS accumulation that enables TRAIL to
activate caspase-8 in RCC. This leads to apoptosis that involves
activation of an amplification loop via the mitochondrial apo-
ptosis pathway. Thus, our mechanistic data indicate that
sorafenib bypasses central resistance mechanisms through a
direct induction ofm breakdown and ROS production. Acti-
vation of this pathway might represent a useful strategy to
overcome the cell-inherent resistance to cancer therapeutics,
including TRAIL, in multiresistant cancers such as RCC.
Apoptotic cell death induced by the death ligand tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)2
plays an important role in immune surveillance and is a major
immune defense mechanism against tumor cells. Conse-
quently, the use of TRAIL, which preferentially kills cancer cells
while sparing non-cancerous tissue, is a promising concept in
anticancer therapy. Recombinant TRAIL and agonistic anti-
bodies against the TRAIL receptors are therefore tested in clin-
ical phase I and II studies (1–3).
Binding of TRAIL to the death receptors DR4 (TRAIL-R1)
and DR5 (TRAIL-R2) initiates receptor oligomerization and,
via the adaptor protein Fas-associated protein with death
domain (FADD), recruitment of the initiator caspase-8 to the
death domain of the activated receptor (4, 5). Formation of this
activation platform, the so-called death-inducing signaling
complex, results in autocatalytic activation of caspase-8. In type
I cells, active caspase-8 triggers, via direct proteolytic pro-
cessing of caspase-3, a caspase cascade to induce apoptotic cell
death. In type II cells, however, the E3-ligase X-linked inhibitor
of apoptosis protein (XIAP) prevents accumulation of active
caspase-3 by marking it for proteasomal degradation (6).
Therefore, in type II cells, efficient caspase-3 activation upon
death receptor signaling requires amplification via the mito-
chondrial apoptosis pathway. Activation of the mitochondrial
pathway is achieved by mitochondrial outer membrane per-
meabilization (MOMP) (7). Upon MOMP, the XIAP inhibitor
second mitochondria-derived activator of caspase/direct IAP-
binding protein with low pI (Smac/DIABLO) is released from the
mitochondrial intermembrane space into the cytosol (8), where
it inhibits XIAP and thereby prevents degradation of active
caspase-3 (9–11). Another important proapoptotic factor that is
released into the cytosol upon MOMP is cytochrome c. Cyto-
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formation of the apoptosome, a multiprotein complex in which
the initiator caspase-9 is activated (12) for processing of caspase-3
and amplification of the caspase cascade.
Upon TRAIL-R ligation, MOMP is induced by caspase-8-
mediated cleavage and activation of BH3-interacting domain
death agonist (Bid), a proapoptotic protein of the B cell lym-
phoma 2 (Bcl-2) family (13–15). The proteins of the Bcl-2 fam-
ily are key regulators of MOMP and show homology in at least
one of four Bcl-2 homology (BH1–4) domains. Antiapoptotic
family members (e.g. Bcl-2, Bcl-xL, and Mcl-1) are character-
ized by the presence of all four BH domains. Proapoptotic
members can be subdivided into the multidomain BH123 ho-
mologs (Bax, Bak, and Bok) and into the large BH3-only sub-
family (e.g. Bid, Bim, Bad, Nbk/Bik, Puma, and Noxa) (16). The
proapoptotic BH123 proteins Bcl-2 associated x protein (Bax)
and Bcl-2 homologous antagonist/killer (Bak) drive MOMP
and are neutralized by antiapoptotic family members. BH3-
only proteins activate Bax and Bak to induceMOMP indirectly
by inhibiting prosurvival Bcl-2 proteins and/or via direct inter-
action with Bax and Bak (17, 18).
Deregulation of these apoptosis signaling pathways accounts
for resistance to anticancer therapies, including the biological
agent TRAIL, which often serves as a prototypical targeted re-
agent to study apoptosis signaling in cancer cells. Strategies to
overcome resistance to TRAIL-induced apoptosis comprise
combinationswithDNA-damaging therapies, including the use
of chemotherapeutic drugs (19) and irradiation (20), or the
inhibition of prosurvival signaling, e.g. the nuclear factor B
(NF-B) pathway (21), inhibition of the proteasome (22, 23), or
inhibition of histone deacetylases (24), all of which have been
shown to sensitize tumor cells for TRAIL. In addition, BH3
mimetics, small molecules like ABT-737 or Obatoclax may
potentiate TRAIL-mediated apoptosis through binding to the
hydrophobic groove at the surface of antiapoptotic Bcl-2 pro-
teins, thereby blocking their prosurvival function (25, 26). Fur-
thermore, the multikinase inhibitor sorafenib sensitizes cancer
cells toward TRAIL through alternative mechanisms, e.g. inhi-
bition of STAT3 (27, 28), and in particular through down-reg-
ulation of the Bak inhibitormyeloid cell leukemia 1 (Mcl-1) (29,
30). Down-regulation of Mcl-1 enables TRAIL to kill cells via
activation of Bak; thus, it can overcome TRAIL resistance of
Bax-deficient cells (31).
Sorafenib is approved for the treatment of advanced renal
cell carcinomas (RCCs) (32–35), a cancer entity that frequently
shows resistance not only to conventional radio- and chemo-
therapy but also to experimental therapywithTRAIL (22).Here
we show that sorafenib overcomes the TRAIL resistance of var-
ious RCC cell lines. Surprisingly, in RCC, sorafenib-induced
down-regulation of Mcl-1 is not causative of the sensitization.
Instead, sorafenib induces caspase- and Bax/Bak-independent
depolarization ofmitochondria accompanied by increasedROS
accumulation. Accumulation of ROS then overcomes the fail-
ure of TRAIL to activate caspase-8 in RCC cells and thereby
enables TRAIL to induce apoptosis.
Results
RCCs frequently display an impressive resistance to antican-
cer therapies, including application of the biological agent
TRAIL. We therefore employed TRAIL as a well defined apo-
ptosis inducer to evaluate strategies to overcome therapy re-
sistance in RCC. To this end, we treated the three RCC cell lines
RCC-KP,RCC-26,andRCC-GW,whichhadrevealedhighresis-
tance toward TRAIL in dose-response experiments, with
TRAIL (50 ng/ml for 24 h) or sorafenib (20 M for 38 h) or
preincubated cells for 14 h with sorafenib prior to TRAIL treat-
ment. Induction of apoptosis was analyzed by flow cytometric
detection of the relative cellular DNA content, and hypodiploid
cells were assumed to be apoptotic. As expected, a TRAIL con-
centration of 50 ng/ml alone did not induce apoptotic DNA
fragmentation in any of the three RCC cell lines (Fig. 1). 20 M
sorafenib also did not induce apoptosis in RCC-GW cells and
only marginally induced apoptosis in RCC-KP and RCC-26
cells. Preincubation of cells with sorafenib, however, strongly
sensitized all cell lines to TRAIL-induced apoptosis. In detail,
45% of RCC-KP, 44% of RCC-26, and 26% of RCC-GW cells
showed a hypodiploid, i.e. apoptotic, phenotype upon com-
bined treatment,whereas treatmentwithTRAILor sorafenib as
single agents resulted in less than 8% and 15% apoptotic cells,
respectively.
It has been shown recently that sorafenib sensitizes tumor
cells to TRAIL by down-regulation of XIAP and, in particular,
by down-regulation of Mcl-1. Thus, we analyzed the influence
of sorafenib on the expression levels of XIAP andMcl-1 in RCC
lines by immunoblotting. The expression levels of XIAP did not
differ in control and sorafenib-treated RCC cell lines (Fig. 1B),
indicating that XIAP down-regulation is not involved in the
reversal of apoptosis resistance. However, the expression of
Mcl-1 was slightly reduced in RCC-KP and RCC-26 cells (but
not in RCC-GW cells), suggesting that sorafenib-induced
Mcl-1 down-regulation might cause TRAIL sensitization. To
investigate the relevance of reduced Mcl-1 expression for the
sensitization of RCC cell lines, we analyzed TRAIL-induced
apoptosis in the presence or absence of siRNA-mediated
knockdown of Mcl-1. In contrast to other cell systems (31),
knockdown of Mcl-1 (Fig. 1C), surprisingly, did not increase
TRAIL-induced apoptosis in RCCcomparedwith controls (Fig.
1D). These results indicate that sorafenib-mediated down-reg-
ulation of Mcl-1 is unlikely to cause sensitization of RCC cell
lines to TRAIL.
To analyze the mechanism underlying the synergism of
sorafenib and TRAIL in RCC, we investigated hallmarks of the
mitochondrial apoptosis signaling cascade and death receptor
signaling. Western blotting analysis showed that the death
ligand TRAIL as a single agent failed to induce caspase-8 pro-
cessing (Fig. 2A). Consistently, events located downstream of
caspase-8 activation, such as Bid cleavage, caspase-3 pro-
cessing, or the release of Smac and cytochrome c into the cyto-
sol, were not detectable upon TRAIL treatment (Fig. 2A). Like-
wise, sorafenib alone did not induce caspase activation or
release of proapoptotic factors into the cytosol. In contrast, a
time course experiment revealed that preincubation of cells
with sorafenib enabled TRAIL to activate caspase-8, as evi-
denced by the detection of the caspase-8 subunits p41/43 and
p18 after 2–4 h of TRAIL treatment. In addition, after 4 h, a p30
subunit was detectable, indicating that caspase-8 was also pro-
ROS induced by sorafenib overcome TRAIL resistance
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cessed via an alternative, previously described pathway (36).
Activation of caspase-8 was accompanied by processing of Bid
to its active form tBid/p15, release of Smac and cytochrome c,
and processing of procaspase-3 to the active subunits (Fig. 2A).
Inaccordancewith thecleavageofBidand the releaseofproapo-
ptotic factors into the cytosol, immunofluorescence staining of
cells with antibodies specific for active conformers of Bax and
Bak, respectively, verified activation of both molecules in re-
sponse to the combined incubation of cells with TRAIL and
sorafenib (Fig. 2B). Thus, although TRAIL as a single agent was
incapable of efficient caspase-8 activation, pretreatment of
RCC cells with sorafenib enabled TRAIL to activate caspase-8,
resulting in Bid cleavage and activation of the mitochondrial
apoptosis pathway.
Figure1.Sorafenib-mediateddown-regulationofMcl-1 isnot involved in thesensitization toTRAIL-inducedapoptosis.A, sorafenib (SF)overcomes the
TRAIL resistance of RCC cell lines. The indicated RCC cells were incubatedwith 50 ng/ml TRAIL for 24 h or 20M sorafenib for 38 h or preincubated for 14 hwith
sorafenib before addition of TRAIL. Apoptotic (hypodiploid) cells were determined by FACS analysis of relative cellular DNA content. TRAIL did not induce
apoptosis in anyof the cell lines. Sorafenibdidnot induce apoptosis in RCC-GWcells andonlymarginally in RCC-KP andRCC-26 cells. Combined treatmentwith
sorafenib and TRAIL potently induced apoptosis in all three cell lines. Top panel, representative flow cytometry histograms of PI-stained cells. The percentage
of hypodiploid, i.e. apoptotic, cells is indicated between markers. Bottom panel, mean  S.D. of triplicates. B, Western blotting analysis revealed down-
regulationofMcl-1 uponSF treatment in RCC-KWandRCC-26 cells. In contrast, XIAP expression levelswere not reduced in anyof the cell lines.C, RCC cellswere
either left untreated or transfected with non-targeting (c) or Mcl-1 siRNA, and knockdown of Mcl-1 was confirmed byWestern blotting analysis. D, after Mcl-1
down-regulation, cells were treatedwith TRAIL, cultured for an additional 24 h, and apoptotic cells were assessed by FACS analysis. None of the cell lines were
sensitized to TRAIL-induced apoptosis upon Mcl-1 down-regulation (mean S.D. of triplicates).
ROS induced by sorafenib overcome TRAIL resistance
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To delineate the activation of the mitochondrial apoptosis
pathway by combined treatment with sorafenib and TRAIL in
more detail, we investigated loss of the mitochondrial mem-
brane potential (m). To this end, cells were incubated with
the cationic dye JC-1, which exhibits specific mitochondrial
localization and red fluorescence in vital cells and cytosolic
Figure 2. Sorafenib enables TRAIL to activate caspase-8 and themitochondrial apoptosis signalingpathway.A, after preincubationwith sorafenib, cells
were treated with TRAIL for the indicated periods of time, and caspase processing, Bid cleavage, and release of Smac and cytochrome c (Cyt c) were analyzed
by immunoblotting. Treatmentof cellswith sorafenibor TRAIL as single agents for 16h inducedneither caspaseprocessingnorBid cleavageor releaseof SMAC
or cytochrome c. In contrast, combined sorafenib/TRAIL treatment resulted in processing of caspase-8 and -3 to the respective active subunits that became
detectable after 4 h. This was accompanied by Bid activation, indicated by increased tBid levels, and release of cytochrome c and Smac into the cytosol. B, cells
were treated with SF, TRAIL, or a combination of both, and activation of Bax and Bak was analyzed by staining the cells with conformation-specific antibodies
(Bax-NT and Bak-NT, respectively) and subsequent flow cytometry. As single agents, sorafenib and TRAIL failed to induce activation of Bax or Bak. However,
preincubation of cells with sorafenib enables TRAIL to activate Bax aswell as Bak. Left panel, representative flow cytometry histograms of immunostained cells.
The percentage of cells positive for conformation-changed Bax or Bak is indicated between markers. Right panel, mean S.D. from triplicates. c, control.
ROS induced by sorafenib overcome TRAIL resistance
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localization and green fluorescence upon loss of m. In con-
trol cells, fluorescence microscopy showed a red dotted stain-
ing pattern, indicating accumulation of JC-1 in the mitochon-
dria. In contrast, upon sorafenib treatment, cells showed a
dose-dependent increase in diffuse (cytosolic) green fluores-
cence (Fig. 3A). FACS analysis of JC-1 green fluorescence inten-
sity revealed loss ofm in almost all cells upon treatmentwith
sorafenib alone and, naturally, also upon combined treatment
with sorafenib andTRAIL (Fig. 3B). Although sorafenib by itself
was sufficient to induce loss of m, it failed, as a single agent,
to induce apoptosis in RCC cells (Fig. 2A).
Mitochondrial dysfunction, such as loss of m, is com-
monly associated with production of reactive oxygen species
(ROS). To analyzewhether sorafenib-induceddepolarization of
the mitochondria is accompanied by increased intracellular
ROS levels, cells were incubated with the cell-permeable dye
CellROX Green, which exhibits green fluorescence and
binding to DNA only upon oxidation. Fluorescence micros-
copy of control cells showed a weak dotted green fluores-
cence pattern in all three cell lines, indicating basal ROS
production at the mitochondria (Fig. 3C, left panel). Upon
treatment with sorafenib, the staining pattern changed to
Figure 3. Sorafenib-inducedmitochondrial depolarization is accompanied by accumulation of reactive oxygen species. A, RCC cell lines were treated
with the indicatedconcentrationof sorafeniband subsequently stainedwith JC-1 toanalyze lossofm. In control cells, JC-1 accumulates inmitochondria and
forms red fluorescent J aggregates, reflecting high mitochondrial membrane potential, whereas green cytosolic fluorescence, indicating low mitochondrial
membrane potential, increases with the concentration of sorafenib. B, RCC cells were treated with TRAIL and sorafenib as single agents or in combination.
Measurement of green JC-1 fluorescence intensity by flow cytometry on a single-cell level revealed that sorafenib, but not TRAIL, as a single agent induces loss
ofm in each of the RCC cell lines. C, cells were treatedwith 20M sorafenib alone or in combinationwith the free radical scavenger NAC. ROS accumulation
was assessed by CellROX Green staining and fluorescence microscopy 6 h after treatment. Control cells showed a weak punctate green fluorescence pattern
that changed to a bright nuclear fluorescence, demonstrating oxidation of CellROXGreen by ROS and binding of the oxidized dye to nuclear DNA. Prevention
of ROS accumulation byNAC inhibits nuclear fluorescence stainingwith CellROX green. In addition, cells with reducedmwere determined by JC-1 staining
and flow cytometry. Treated cells were compared with controls. In contrast to ROS accumulation, sorafenib-induced loss of m was not inhibited by NAC.
ROS induced by sorafenib overcome TRAIL resistance
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bright nuclear fluorescence, demonstrating oxidation of Cell-
ROXGreen and binding of oxidized CellROXGreen to nuclear
DNA. Co-incubation of sorafenib-treated cells with the anti-
oxidative agent N-acetylcysteine (NAC) efficiently prevented
bright nuclear fluorescence, indicating inhibition of ROS accu-
mulation (Fig. 3C, left panel). However, although NAC effi-
ciently prevented sorafenib-induced ROS accumulation, it
failed to prevent sorafenib-induced depolarization of mito-
chondria, as shown by JC-1 staining and FACS analysis of
sorafenib- and NAC-treated cells (Fig. 3C, right panel). Hence,
sorafenib-induced mitochondrial depolarization is indepen-
dent and occurs upstream of ROS accumulation.
To further study the role of caspases in the mechanism
underlying sorafenib-mediated sensitization of RCC cells to-
ward TRAIL-induced cell death, RCC cells were pretreated
with sorafenib and subsequently exposed to TRAIL in the pres-
ence of the caspase-8 inhibitor Z-LETD-fmk, the caspase-3/7
inhibitor Z-DEVD-fmk, or the pan-caspase inhibitor Q-VD-
OPh. After 6 h of incubation, cells were stained with annexin
V-FITC/PI. Flow cytometric analysis revealed that all inhibitors
potently reduced the proportion of apoptotic cells, withQ-VD-
OPh showing the strongest effect (Fig. 4A), almost completely
inhibiting sorafenib/TRAIL-induced apoptosis. Interestingly,
FACS analysis of identically treated cells stained with JC-1
showed that Q-VD-OPh had no effect on sorafenib-induced
mitochondrial depolarization (Fig. 4B). Also, like mitochon-
drial depolarization, sorafenib-induced ROS accumulation was
not influenced by Q-VD-OPh and, thus, is independent of
caspase activity, as shown by the bright CellROX Green stain-
ing induced by sorafenib in Q-VD-OPh-pretreated RCC cells
(Fig. 4C). Sorafenib-induced depolarization of mitochondria
and ROS accumulation thus are independent and functionally
upstream of caspase activation.
TRAIL alone did not induce caspase-8 activation in RCC-26
cells but efficiently triggered processing of caspase-8 in cells
preincubated with sorafenib (Fig. 2A). Therefore, we investi-
gated whether sorafenib-induced accumulation of ROS is
instrumental for caspase-8 activation upon TRAIL treatment.
To this end, RCC cells were treated with sorafenib and TRAIL,
and active caspase-8 was labeled with the fluorescent irrevers-
ible caspase-8 inhibitor FAM-LETD-fmk. Subsequent flow
cytometric analysis revealed that the presence of NAC strongly
reduced the number of cells positive for active caspase-8 label-
ing upon sorafenib/TRAIL treatment. For example, only 4% of
RCC-26 control cells were positive for active caspase-8,
whereas about 38% of sorafenib/TRAIL-treated cells were flu-
orescent for active caspase-8 (Fig. 5A). Inhibition of ROS accu-
mulation by co-incubation with NAC strongly reduced the
fraction of RCC-26 cells positive for active caspase-8 from 38%
to 15% (Fig. 5A). NAC-mediated inhibition of sorafenib/
TRAIL-induced caspase-8 processing was confirmed by immu-
noblotting. The processing of caspase-8 to its subunits in
RCC-26 cells exposed to sorafenib and TRAIL was impaired by
the ROS scavenger NAC (Fig. 5B), indicating that ROS produc-
tion by sorafenib is crucial for TRAIL to activate caspase-8.
We next asked whether the sensitizing effect of sorafenib
toward TRAIL-induced apoptosis is mediated by excessive
ROS production. Therefore, RCC cells were preincubated for
Figure 4. Sorafenib-induced depolarization and ROS production are inde-
pendent of caspase activity. A, in addition to SF and TRAIL, the caspase-3/7
inhibitor Z-DEVD-fmk, the caspase-8 inhibitor Z-LETD-fmk, or the pan-caspase
inhibitor Q-VD-OPh was added at a final concentration of 20 M to the culture
medium of RCC-26 cells After 6 h, cells were harvested, and apoptosis was ana-
lyzed by annexin V-FITC/PI staining and flow cytometry. Indicated are early
(annexin V-FITC/PI) and late apoptotic (annexin V-FITC/PI) cells. Induc-
tionof apoptosis by combined sorafenib/TRAIL treatment is strongly reducedby
Z-DEVD-fmk, Z-LETD-fmk, and Q-VD-OPh. B, cells were treated with sorafenib in
the absence or presence of 20 M Q-VD-OPh (QVD), and loss of m was ana-
lyzedby JC-1 staining and FACS analysis. Treated cellswere comparedwith con-
trols. In contrast to apoptosis, the broad-range pan-caspase inhibitor Q-VD-OPh
does not inhibit sorafenib-induced loss ofm. C, cells were treated as in B, and
accumulation of ROSwas analyzed by CellROXGreen staining. The pan-caspase
inhibitor Q-VD-OPh does not inhibit sorafenib-induced ROS accumulation.
ROS induced by sorafenib overcome TRAIL resistance
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1 hwithNACor left untreated prior to addition of sorafenib for
14 h. Then TRAIL was added, and another 6 h later, induction
of apoptosiswas assessed by flow cytometric analysis of annexin
V-FITC/PI-stained cells. In cells preincubated with NAC, the
proportion of apoptotic cells (early apoptotic cells, annexin
V-FITC/PI; late apoptotic cells, annexin V-FITC/PI)
was reduced by50% in each cell line, i.e. from 65% to 30% in
RCC-KP cells, from 60% to 28% in RCC-26 cells, and from
36% to 19% in RCC-GW cells (Fig. 5C). These data demon-
strate that induction of apoptosis by the combination of
sorafenib and TRAIL is strongly reduced upon blocking of
ROS accumulation. Because inhibition of ROS accumulation
by NAC abrogates sorafenib-mediated sensitization of RCC
cells toward TRAIL-induced apoptosis, we conclude that
Figure 5. Sorafenib-induced ROS accumulation enables TRAIL to activate caspase-8 and is responsible for sensitization to TRAIL-induced cell death.
A, RCC cells were treatedwith sorafenib, TRAIL, and sorafenib/TRAIL in the absence or presence of NAC to prevent ROS accumulation. 8 h post-treatment, cells
with active caspase-8were detected by flow cytometry using the FAM-FLICA caspase-8 detection kit. The ROS scavenger NACblocks sorafenib/TRAIL-induced
caspase-8 activation. B, RCC-26 cells were treated as in A, and caspase-8 (C8) cleavage was analyzed by immunoblotting. Following combined treatment of
sorafenib/TRAIL, pro-caspase-8 is processed to its active subunits. Proteolytic processingof caspase-8 is strongly reduced in thepresenceof the ROS scavenger
NAC. C, induction of apoptosis was quantified by annexin V-FITC/PI staining and flow cytometry. Cells positive for annexin V-FITC (phosphatidylserine
exposure) and negative for PI staining represent early apoptotic cells, whereas late apoptotic cells are positive for both annexin V-FITC and PI. Flow cytometric
analysis revealed that induction of apoptosis by combined incubation with sorafenib and TRAIL is strongly reduced upon NAC-mediated inhibition of ROS
accumulation. Panels showmean S.D. of triplicates.
ROS induced by sorafenib overcome TRAIL resistance
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ROS accumulation is crucial for the TRAIL-sensitizing effect
of sorafenib.
To test whether sorafenib-induced ROS production is a gen-
eral mechanism that sensitizes cells to TRAIL-induced apopto-
sis, we incubatedMel-2a melanoma and DU145 prostate carci-
noma cells with sorafenib and TRAIL. In both cell lines,
sorafenib induced depolarization of themitochondria and ROS
formation (Fig. 6A). Moreover, sorafenib sensitizedMel-2a and
DU145 cells to TRAIL-induced apoptosis, whichwas efficiently
inhibited by the ROS scavenger NAC (Fig. 6B).
During canonical activation of the intrinsic apoptosis path-
way, the BH123 proteins Bax andBakmediate the dissipation of
the mitochondrial membrane potential. To elucidate whether
Bax and Bak are also involved in the depolarization of mito-
chondria induced by sorafenib, we used HCT116-WT colon
cancer cells and the isogenic knockout cell lineHCT116-Bax//
Bak/ (37). Fluorescence microscopy of JC-1-stained cells
showed that sorafenib induced depolarization in both cell lines
in a concentration-dependent manner (Fig. 7A), which became
detectable already 1–3 min after the addition of sorafenib (fig.
7B). These results demonstrate that sorafenib-induced depo-
larization of mitochondria is a very early event and, more
intriguingly, not mediated by Bax or Bak. Besides Bax and Bak,
the opening of the mitochondrial permeability transition pore
(MPTP) induces MOMP and causes loss of m. However,
cyclosporin A (CsA), which acts as a potent inhibitor of MPTP
opening, did not prevent sorafenib-induced mitochondrial
depolarization in HCT116-WT and HCT116-Bax//Bak/
cells (Fig. 7C), demonstrating that sorafenib-induced depolar-
ization is independent of both Bax/Bak and the MPTP.
The rapid Bax/Bak- and MPTP-independent mitochondrial
depolarization induced by sorafenib resembles the mechanism
induced by classical uncouplers of the mitochondrial respira-
tory chain, like carbonyl cyanide m-chlorophenylhydrazone
(CCCP). We therefore next asked whether CCCP sensitizes
RCC-26 cells to TRAIL-induced apoptosis in a ROS-dependent
mechanism. As supposed, flow cytometric analysis of JC-1-
stained cells showed that CCCP treatment induced dissipation
of m (Fig. 8A), which was accompanied by ROS accumula-
tion, as shown by CellROX staining (Fig. 8B). Furthermore,
incubation with CCCP also increased TRAIL-induced apopto-
sis, evidenced by annexin V-FITC/PI staining (Fig. 8C). Both
effects induced by CCCP, increased ROS accumulation and
increased apoptosis induction by TRAIL, were considerably
reduced by preincubation with NAC. However, in the presence
of NAC, a small portion of cells was still positive for annexin
V-FITC/PI, indicating that CCCP in combination with TRAIL
might also, albeit to a lesser extent, induce necrosis-like cell
death. Comparable with sorafenib, CCCP-induced mitochon-
drial depolarization was detectable 1–3 min upon treatment
and independent of Bax and Bak (Fig. 7D).
As mitochondrial depolarization is independent of Bax or
Bak, we next asked whether, in RCC cells also, activation of
caspase-8 and induction of apoptosis by combined treatment
with TRAIL and sorafenib is independent of Bax and Bak. To
this end, expression of Bax and Bak in RCC-26 cells was
down-regulated by transfection with appropriate siRNAs, and
cells were subsequently incubated with sorafenib and TRAIL.
Despite efficient knockdown of Bax and Bak expression in
RCC-26 cells (Fig. 9A), caspase-8 activation upon combined
sorafenib/TRAIL treatment was not reduced (Fig. 9B), indicat-
ing that caspase-8 activation is Bax- and Bak-independent.
However, despite unaltered caspase-8 activation, apoptosis
induction by sorafenib/TRAIL was decreased but not com-
pletely inhibited by knockdownof Bax andBak (Fig. 9C). In cells
transfected with control siRNA, 60% of the cells were positive
for annexin V-FITC staining upon sorafenib/TRAIL treatment.
This was reduced to 40% upon transfection of the cells with Bax
and Bak siRNA. Transfection of cells with Bak siRNA did not
completely abolish Bak expression. Thus, activation of residual
Bak, mediated by caspase-8-cleaved and -activated Bid, might
account for the remaining induction of apoptosis. To com-
pletely block the mitochondrial amplification loop and to
inhibit activation of residual Bak by tBid, we additionally down-
regulated Bid expression to Bax and Bak (Fig. 10A). Similar to
Bax/Bak knockdown, simultaneous knockdown of Bid, Bax,
and Bak reduced, but did not completely block, sorafenib/
TRAIL-induced apoptosis (Fig. 10B). This indicates that Bax/
Bak-regulated events of mitochondrial apoptosis signaling only
partially contribute to apoptosis mediated by the combination
Figure 6. Mitochondrial depolarization, ROS accumulation, and induction of apoptosis upon sorafenib/TRAIL treatment in cancer cell lines derived
from different tissues. A, Mel-2a melanoma and DU145 prostate cancer cells were treated with sorafenib and stained with JC-1 or CellROX Green to analyze
loss ofm and ROS accumulation, respectively. Similar to RCC cells, sorafenib inducedmitochondrial depolarization and ROS accumulation in both cell lines.
B, flow cytometric annexin V-FITC/PI staining revealed that induction of apoptosis by combined treatment with sorafenib and TRAIL was strongly reduced by
NAC in Mel-2a and DU145 cells.
ROS induced by sorafenib overcome TRAIL resistance
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of sorafenib/TRAIL. Overall, induction of apoptosis upon
sorafenib/TRAIL treatment appears to be rather mediated by a
type I pathway, which might further boost downstream activa-
tion of the mitochondrial pathway.
Discussion
Resistance to classical chemotherapy or targeted treatment
modalities, including TRAIL, is the major obstacle in oncology.
RCC is one of the most chemoresistant tumor types, and only
the introduction of multitargeted kinase inhibitors has pro-
vided some, rather limited, therapeutic progress. Here we pro-
vide evidence for an interesting new mechanism of how
sorafenib may be utilized to overcome resistance to apoptosis
induction. As a model agent, we employed the death ligand
TRAIL, which induces apoptosis through a Bax/Bak-controlled
(type II) mitochondrial pathway in most solid tumors.
Themultikinase inhibitor sorafenib is approved for the treat-
ment of advanced hepatocellular and renal cell carcinoma and
shows promising antitumor activity as a single agent. However,
primary and acquired drug resistance decreases the rate and
duration of tumor response and impedes survival benefits (38,
39). Nevertheless, the multiple targets of sorafenib make it an
attractive choice for combination therapy with TRAIL, and,
consequently, sorafenib was shown to sensitize various cancer
cells to TRAIL-induced apoptosis (30, 40, 41). Here we present
a new mechanism by which sorafenib overcomes the TRAIL
resistance of RCC cells. Increased ROS levels, generated upon
sorafenib-inducedmitochondrialdepolarization, enableTRAILto
activate caspase-8 and to induce cell death.
The anticancer effect of sorafenib is assumed to rely on its
ability to inhibit cancer cell proliferation and to block angiogen-
esis through inhibition of Raf, PDGF receptor, and VEGF
receptor (38). In addition, sorafenib induces apoptosis and sen-
sitizes tumor cells to chemo- and radiotherapy by modulating
STAT3 (42), Akt (43), NF-B (29, 44), and apoptosis signaling
pathways. Particularly sorafenib-mediated down-regulation of
Mcl-1 seems to be crucial to sensitize cancer cells to TRAIL-
induced cell death (29, 45). Down-regulation of Mcl-1, a spe-
cific Bak antagonist, lowers the apoptotic threshold and enables
TRAIL to induce apoptosis via a Bak-dependent mitochondrial
pathway. Hence, even TRAIL resistance caused by Bax defi-
ciency is overcome by sorafenib-induced Mcl-1 down-regula-
tion (31). However, RCC cells treated with sorafenib do not
show consistently decreased levels of Mcl-1, indicating that, in
these cells, down-regulation of Mcl-1 is unlikely to be involved
in overcoming TRAIL resistance. Furthermore, the specific
siRNA-mediated knockdown of Mcl-1 did not affect TRAIL
resistance in RCC cells.
In this study, we further demonstrate that sorafenib sensi-
tizes RCCcells to apoptosis induced byTRAIL through amech-
anism that depends on sorafenib-induced ROS accumulation.
This conclusion is supported by the prevention of sorafenib-
induced ROS accumulation by NAC, which results in the inhi-
bition of sorafenib/TRAIL-induced apoptosis. Importantly,
NAC does not inhibit mitochondrial depolarization, indicating
that depolarization per se is insufficient to enhance TRAIL-
induced apoptosis and that, rather, generation of ROS down-
stream of mitochondrial depolarization provokes sensitization
toward TRAIL. It has been shown that, in FADD-deficient
acute lymphoblastic leukemia cells, ROS induction is a critical
regulator of necroptotic cell death induced by a Smac mimetic
in combination with TNF. Consistent with the definition of
necroptosis, this cell death is caspase-independent (46, 47). In
contrast, ROS-mediated cell death induced by sorafenib/
TRAIL is blocked by the caspase inhibitor Q-VD-OPh, indicat-
ing induction of apoptotic cell death.
ROS production has also been reported previously during
sorafenib-mediated cytotoxicity in hepatocarcinoma and EBV-
transformed B cells (48, 49). The increased ROS production
might be a consequence of activation of a NAD(P)H oxidase
(48) or sorafenib-induced inactivation of mitochondrial com-
plex I (NADH dehydrogenase) (50). In neuroblastoma cells,
Figure7. Sorafenib-inducedmitochondrial depolarizationupon sorafenib/
TRAIL treatment is independent of Bax and Bak and the MPTP. A,
HCT116-WT cells and isogenic HCT116-Bax//Bak/ cells were treated
with sorafenib and stained with JC-1 to analyze loss of mitochondrial mem-
branepotential. Fluorescencemicroscopy (top panels) showeddecreased red
and increased green fluorescence upon treatment with sorafenib in both cell
lines, indicating that loss of m is independent of Bax and Bak. B, HCT116-
Bax//Bak/ cells were treated with sorafenib for the indicated time peri-
ods and stainedwith JC-1. Loss ofm is detectable 1–3min after treatment
in almost all cells. C, in addition to sorafenib, HCT116-WT and HCT116-Bax/
/Bak/ cells were preincubated with CsA to block MPTP opening. Upon
treatment, cells were stainedwith JC-1 and analyzed by fluorescencemicros-
copy. CsA failed to prevent sorafenib-induced mitochondrial depolarization
in HCT116-WT and HCT116-Bax//Bak/ cells, demonstrating that
sorafenib-induced depolarization is independent of bothMPTP and Bax/Bak.
ROS induced by sorafenib overcome TRAIL resistance
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down-regulation of complex I, induced by sorafenib, results in
caspase- and Bcl-2 independent loss of m that is accompa-
nied by increased ROS levels and induction of cell death (50). In
contrast to neuroblastoma cells, however, inwhich the decrease
of m became evident after 12 h of treatment, in RCC cells,
depolarization was already detectable 1–3min after addition of
sorafenib. This almost instant depolarization makes a mecha-
nism involving down-regulation of the NADH dehydrogenase
most unlikely.
Interestingly, it has been shown that sorafenib, in contrast to
the kinase inhibitors imatinib, dasatinib, and sunitinib, can
directly impair mitochondrial function. Sorafenib can act as an
inhibitor of the oxidative phosphorylation complexes and/
or as an uncoupler of oxidative phosphorylation (51), and both
mechanisms might explain the rapid sorafenib-induced mito-
chondrial depolarization. Although the exact mechanism of
ROS induction is elusive, uncoupling of oxidative phosphory-
lation by sorafenib is compatible with our finding that
sorafenib-mediated depolarization is independent of Bax, Bak,
and opening of the mitochondrial permeability transition pore.
In line with this hypothesis, uncoupling of oxidative phosphor-
ylation is accompanied by generation of ROS and results in
sensitization toward TRAIL, as shown for the classical uncou-
pler CCCP. CCCP sensitizes human colon carcinoma cells to
Figure8.CCCP-inducedmitochondrialdepolarizationandROSaccumulationsensitizeRCC-26cells toTRAIL.A, RCC-26cellswere treatedwithCCCPand
stained with JC-1 to analyze loss of mitochondrial membrane potential. Fluorescencemicroscopy (top panels) and FACS analysis (bottom panels) showed loss
of red fluorescence and increase in green fluorescence upon CCCP treatment in all cells, indicating loss ofm. B, RCC-26 cells were treated with CCCP alone
or in combination with the free radical scavenger NAC. As shown by CellROX Green staining, CCCP-induced ROS accumulation was inhibited by NAC. C, in
addition to TRAIL and CCCP, RCC-26 cells were pretreated with NAC. Induction of apoptosis was quantified by flow cytometric detection of cells positive for
annexin V-FITC (phosphatidylserine exposure) and negative for PI staining (intact plasmamembrane), i.e. early apoptotic, and detection of annexin V-FITC/PI
positive (late apoptotic) cells. FACSmeasurement revealed that CCCP sensitizes cells to TRAIL-induced apoptosis. Sensitization to TRAILwas inhibited byNAC.
Left panel, representative flow cytometry histograms. Right panel, mean S.D. of triplicates. D, HCT116-Bax//Bak/ cells were treated with CCCP for the
indicated time periods and stained with JC-1. Loss of m is detectable 1–3 min after treatment in almost all cells.
ROS induced by sorafenib overcome TRAIL resistance
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TRAIL-induced apoptosis by enhancing caspase-8 activation
via generation of ROS (52). ROS, in turn, modulate apoptosis
signaling by assisting in the activation of initiator caspases (53).
Likewise our results indicate that ROS act as upstream signaling
molecules that facilitate caspase-8 activation after receptor
ligation, ultimately resulting in induction of apoptosis in RCC.
ROS accumulation, in contrast to cell death, is not inhibited by
caspase inhibitors. ROS accumulation is therefore caspase-
independent and represents an upstream event in sorafenib/
TRAIL-induced apoptosis. Furthermore, sorafenib/TRAIL-
Figure 9. Caspase-8 activation andapoptosis upon combined treatmentwith sorafenib andTRAIL is independent of Bax andBak.A, RCC-26 cellswere
transfected with non-targeting or Bax- and Bak-targeting siRNA. After 24 h, protein extracts were prepared and analyzed by Western blotting to confirm
down-regulation of the targeted proteins. c, control. B, after down-regulation of Bax and Bak, cells were treated with TRAIL and sorafenib. Cells with active
caspase-8were detected by flow cytometry using the FAM-FLICA caspase-8 detection kit. Measurement revealed that knockdown of Bax and Bak did not
inhibit caspase-8 activation by combined treatment of cells with sorafenib and TRAIL. C, cells were treated as in B, and apoptosis was quantified by flow
cytometric detection of annexin V-FITC/PI-positive cells. Down-regulation of Bax and Bak decreased but did not prevent sorafenib/TRAIL-induced
apoptosis.
ROS induced by sorafenib overcome TRAIL resistance
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triggered caspase-8 activation is inhibited by NAC, indicating
that ROS accumulation plays a causal role in facilitating
caspase-8 activation by TRAIL.
When caspase-8 is activated, however, additional sorafenib-
induced mechanisms are likely to amplify TRAIL-induced
caspase-8 activation and apoptosis in RCC cells. Such an ampli-
fication of caspase-8 activation via the mitochondrial pathway
upon depolarization and ROS accumulation has been shown
for TRAIL-resistant human colon carcinoma cell lines. Depo-
larization and ROS accumulation induced by CCCP sensitizes
these cells to TRAIL-induced caspase-8 activation and apopto-
sis, but complete processing of caspase-8 in response to TRAIL
requires a functional mitochondrial amplification loop (52). In
RCC cells, the initial step in overcoming TRAIL resistance
seems to be increased TRAIL-induced caspase-8 activation
facilitated by sorafenib-mediated ROS accumulation, which
enables the death receptors to kill cells via a type I, largely Bax/
Bak-independent apoptosis pathway.However, participation of
the mitochondrial cell death pathway in RCC cell lines upon
sorafenib/TRAIL treatment is obvious because of the reduced
induction of apoptosis upon Bax and Bak knockdown. Thus,
it is likely that enhancement of the mitochondrial amplifica-
tion loop, e.g. by down-regulation of Mcl-1, further boosts
sorafenib/TRAIL-induced apoptosis.
Both the death ligand TRAIL and sorafenib have been pro-
posed as promising antitumor agents, although their therapeu-
tic use is restricted because of primary and acquired resistance
of tumors. However, we show here that the combined use of
TRAIL and sorafenib can overcome resistance of various RCC
cell lines. Based on the presented data, we suggest a new path-
way that depends on sorafenib-induced ROS accumulation,
which, in turn, mediates increased caspase-8 activation (Fig.
11). This mechanism explains the sensitization of RCC cells to
TRAIL-induced cell death by sorafenib. Importantly, we show
that sorafenib-induced depolarization and ROS accumulation
are not confined to RCC and might be more generally involved
in sorafenib/TRAIL-induced apoptosis. Thus, the combined
use of TRAIL and sorafenib might be a useful strategy to
broaden the therapeutic efficacy of both agents. Interestingly,
although our finding of sorafenib-induced ROS production in
mitochondria is so far restricted to in vitro settings, elevated
serum levels of advanced oxidation protein products have been
recently associated with improved overall survival of sorafenib-
treated patients (48).
Experimental procedures
Cell culture
RCC lines were cultured as described previously (54). In
brief, cells were grown in RPMI 1640 medium supplemented
with 10% FCS, 100 units/ml penicillin, and 0.1 mg/ml strepto-
mycin (Life Technologies). HCT116 wild-type cells and the iso-
genic double knockout subline HCT116-Bax//Bak/ were
kindly provided by Dr. R. J. Youle, NIH (Bethesda, MD) (37).
Cells were grown in DMEM supplemented with 10% FCS,
100,000 units/liter penicillin, and 0.1 g/liter streptomycin at
37 °C with 5% CO2 in a humidified atmosphere. Media and
culture reagents were from Invitrogen.
Figure 10. Combined knockdown of Bax, Bak, and Bid does not prevent
sorafenib/TRAIL-induced apoptosis. A, RCC-26 cells were transfected with
non-targeting or Bax-, Bak-, and Bid-targeting siRNA. After 24 h, protein
extracts were prepared and analyzed by Western blotting to confirm the
down-regulationof the targetedproteins. c, control. B, after combineddown-
regulation of Bax, Bak, and Bid, cells were treated with TRAIL and sorafenib,
and the proportion of annexin V-FITC/PI-positive cells was detected by flow
cytometry. Measurement revealed that the combined knockdown of Bax,
Bak, and Bid attenuated, but did not prevent, sorafenib/TRAIL-induced
apoptosis.
Figure 11. Sensitization of cancer cells toward TRAIL-induced apoptosis
by sorafenib. Sensitization of cancer cells to TRAIL-induced apoptosis is
mediated by a classical mechanism, including down-regulation of Mcl-1,
which activates the Bax/Bak-triggeredmitochondrial caspase cascade. Alter-
natively, as shown in this study, sorafenib can overcome TRAIL resistance by
Bax/Bak-independent dissipation of the mitochondrial membrane potential,
resulting in ROS accumulation and increased activation of caspase-8.
ROS induced by sorafenib overcome TRAIL resistance
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Antibodies and reagents
Anti-Smac mAb (2954), anti-caspase-8 (1C12) mAb (9746),
anti-Bid (2002), and anti-XIAP mAb (3B6) (2045) were pur-
chased from Cell Signaling Technology, Inc. Anti-Bak mAb
(clone TC102) was from Calbiochem (Merck). Anti-Bax mAb
(clone YTH-2D2) was purchased fromTrevigen (Gaithersburg,
MD), and anti-Mcl-1 (H-260) was from Santa Cruz Biotechnol-
ogy. Anti-caspase-3 antibody (AF605) was from R&D Systems
(Wiesbaden-Nordenstadt, Germany), and anti-actinmAb (AC-
74) was from Sigma-Aldrich (Taufkirchen, Germany). Second-
ary anti-rabbit, anti-goat, and anti-mouse HRP-conjugated
antibodies were from Promega (Mannheim, Germany) or
Southern Biotechnology Associates (Birmingham, AL). RNase
A was from Carl Roth GmbH (Karlsruhe, Germany). Recombi-
nant human TRAIL was from R&D Systems. Sorafenib (BAY
43-9006) was from Enzo Life Sciences GmbH (Lörrach, Ger-
many). NAC was from Sigma-Aldrich. The pan-caspase inhib-
itor Q-VD-OPh, the caspase-3 inhibitor Z-DEVD-fmk, and the
caspase-8 inhibitor Z-LETD-fmk were purchased fromMerck.
Small interfering RNA
SMARTPool On-Target plus Mcl-1, Bid, Bax, Bak, and con-
trol siRNAs were purchased from Dharmacon. Transfection of
cells was carried out by use of DharmaFECT transfection re-
agent 1 according to the instructions of the manufacturer.
Down-regulation of the respective proteins was confirmed by
immunoblotting 24 h after transfection.
Immunoblotting
After trypsination, cells were washed twice with ice-cold PBS
and lysed in 10mMTris-HCl (pH 7.5), 137mMNaCl, 1% Triton
X-100, 2 mM EDTA, 1 M pepstatin, 1 M leupeptin, and 100
M PMSF. Protein concentration was determined using the
Thermo Scientific Pierce BCA protein assay kit (Life Technol-
ogies). Equal amounts of proteinwere separated by SDS-PAGE,
electroblotted onto a nitrocellulose membrane, and visualized
as described previously (55). For analysis of cytochrome c and
SMAC release, cytosolic extracts were prepared according to a
method described previously (55). Briefly, after induction of
apoptosis, cells were harvested, washed in PBS, equilibrated in
hypotonic buffer (20 mM HEPES (pH 7.4), 10 mM KCl, 2 mM
MgCl2, and 1mMEDTA) supplementedwith 100MPMSF and
0.75 mg/ml digitonin (Sigma-Aldrich) and incubated on ice for
3 min. Debris was pelleted by centrifugation at 10,000 	 g at
4 °C for 5 min, and the supernatant was subjected to Western
blotting analysis.
Mitochondrial outermembrane permeabilization
Cells were harvested by trypsination and collected by centrif-
ugation at 300	 g at 4 °C for 5min.Mitochondrial outer mem-
brane permeabilization was assessed by staining the cells with
JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-benzimidazolyl-
carbocyanin iodide, Life Technologies). JC-1 is a cationic dye
that exhibits membrane potential-dependent accumulation
and formation of red fluorescent J aggregates in mitochondria
with a high membrane potential. At low membrane potential
(upon MOMP), JC-1 shows a cytosolic green fluorescence.
Mitochondrial permeability transition was analyzed by flow
cytometry, and cells with increased green fluorescence were
assumed to be cells with reduced m.
Detection of apoptotic cell death by flow cytometry
DNA fragmentation was analyzed as described previously
(56). Briefly, cells were harvested and collected by centrifuga-
tion at 300	 g for 5 min, washed with PBS at 4 °C, and fixed in
PBS/2% (v/v) formaldehyde on ice for 30 min. After fixation,
cells were incubated with ethanol/PBS (2:1, v/v) for 15 min on
ice, pelleted, and resuspended in PBS containing 40 g/ml
RNase A. After incubation for 30 min at 37 °C, cells were pel-
leted and finally resuspended in PBS containing 50 g/ml pro-
pidium iodide. Relative cellular DNA content was quantified
using a FACScan (BDBiosciences), and the fraction of hypodip-
loid cells was calculated using CELLQuest software. Data are
given in percent hypodiploid (subG1), which reflects the num-
ber of apoptotic cells. Alternatively, cell death was determined
by staining cells with annexin V-FITC and propidium iodide
(PI) (57). Briefly, cells were washed twice with cold PBS and
resuspended in 10 mM HEPES (pH 7.4), 140 mM NaCl, and 2.5
mMCaCl2 at 1	 106 cells/ml. To 100l of the solution (1	 105
cells), 5l of annexinV-FITC (BDBiosciences) and 10l PI (20
mg/ml, Sigma-Aldrich) were added. Analysis was performed
using a FACScan and CELLQuest software (BD Biosciences).
Detection of Bax/Bak conformational change
Activation of Bax and Bak, i.e. their conformational change
and exposure of anN-terminal epitope, was detected by the use
of primary antibodies specific for the Bax or Bak N-terminal
domains (Bax-NT from Upstate Biotechnology and Bak-NT
from Merck) and fluorescently labeled secondary antibodies.
After fluorescent staining, cells were subjected to flow cytom-
etry (58). In brief, 1	 105 cells were harvested, washed in PBS,
and fixed for 30 min with 0.5% paraformaldehyde in PBS. After
washing, the cells were resuspended in PBS supplemented with
1% FCS and 0.1% saponin and incubated with the Bax-NT- or
Bak-NT-specific antibody. Thereafter, cells were washed in
PBS and incubated with a secondary FITC-labeled goat-anti-
rabbit or goat-anti-mouse IgG (H  L) antibodies (Jackson
ImmunoResearch Laboratories,Newmarket, UK) at a final con-
centration of 1 g/ml for 30 min at 4 °C in the dark. After
washing and resuspension, cells were immediately analyzed by
flow cytometry.
Caspase-8 activation
Cells with active caspase-8 were detected using the FAM-
FLICATM caspase-8 assay kit (Immunochemistry Technology)
according to the instructions of the manufacturer. This kit
employs a carboxyfluorescein-labeled fluoromethyl ketone
peptide inhibitor of caspase-8 (FAM-LETD-fmk) that is cell-
permeable and a non-cytotoxic fluorochrome.
Detection of ROS
ROS in cells were analyzed by use of the fluorogenic Cell-
ROXGreen reagent (Invitrogen, Life Technologies) according
to the instructions of the manufacturer. In brief, 1 	 105 cells
were plated in a 12-well plate and incubated with the indicated
ROS induced by sorafenib overcome TRAIL resistance
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drugs. Upon treatment, CellROX reagent was added to a final
concentration of 5 M, and cells were incubated for 60 min at
37 °C. Microscopy images were taken using an Axiovert 200
fluorescence microscope (Carl Zeiss, Inc.) equipped with a
Hamamatsu ORCA-ER digital camera using Openlab software
(Improvision).
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